Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans

Metsera's amylin analog, MET-233i, demonstrated 8.4% placebo-adjusted weight loss at Day 36 in a Phase 1 trial, positioning it as a potential competitor in the increasingly crowded weight-loss drug market dominated by companies like AbbVie, Eli Lilly and Novo Nordisk. The drug's 19-day half-life suggests the possibility of monthly dosing, and the company plans to release data from a monotherapy trial later this year, as well as data from a co-administration trial of MET-233i with its GLP-1 drug candidate early next year.

Analysis

Metsera's amylin analog, MET-233i, has demonstrated compelling early-stage efficacy, achieving an 8.4% placebo-adjusted weight loss at Day 36 in a Phase 1 study involving nondiabetic individuals with obesity or who are overweight, using five weekly 1.2-mg doses. This result positions MET-233i as a noteworthy contender in the rapidly evolving and highly competitive amylin analog market, which has seen significant recent investment, including AbbVie's $350 million upfront payment for a Phase 1 asset and Roche's $1.65 billion commitment for Zealand Pharma's candidate. While cross-trial comparisons warrant caution, MET-233i's early weight loss data appears more potent than Zealand's petrelintide (up to 6.9% at 16 weeks) and Novo Nordisk's cagrilintide (5.9% at Week 16). A key differentiating factor for MET-233i is its reported 19-day half-life, which Metsera claims is the most durable among amylin analogs in clinical development, potentially enabling a convenient once-monthly dosing regimen. The company also reported mild, dose-dependent gastrointestinal adverse events, primarily in the first week, with placebo-like tolerability at anticipated starting doses. Metsera is strategically advancing MET-233i, with monotherapy trial data (including dose titration and monthly dosing) expected late this year and co-administration results with its GLP-1 candidate (also targeting monthly dosing) anticipated early next year, aiming for a once-monthly combination therapy. The overall market sentiment towards this development is strongly positive, with specific high positive sentiment for Metsera (MTSR), contrasting with a slightly negative sentiment for Novo Nordisk (NVO), reflecting the potential for increased competition.

Key Decisions for Investors

• Investors should closely monitor Metsera's upcoming MET-233i monotherapy data expected late this year, which will include dose titration, and the GLP-1 combination data early next year to validate sustained efficacy, full tolerability profile, and the viability of the proposed monthly dosing regimen.
• Given the high strategic value demonstrated by recent M&A activity in the amylin analog space (e.g., AbbVie, Roche deals), positive progression of MET-233i could position Metsera (MTSR) as an attractive target for partnership or acquisition.
• Holders of competitor stocks, such as Novo Nordisk (NVO), should consider the potential for increased competition from emerging differentiated amylin analogs like MET-233i, especially if its monthly dosing and tolerability profile prove advantageous.
• Evaluate the full tolerability data from Metsera's upcoming trial with dose titration, as this will be a critical determinant of MET-233i's competitive positioning against established and pipeline therapies from major players like Eli Lilly (LLY) and Novo Nordisk (NVO).